In metastatic prostate cancer, miR-135a inhibited tumor progression by decreasing epidermal growth factor receptor (EGFR)29, and its silencing resulted in increased AR axis activity, thus contributing to disease progression65. This evidence concerns the gene EGFR and metastatic prostate carcinoma.